This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Applied Genetic Technologies Dirección

Dirección controles de criterios 1/4

Información clave

Sue Washer

Chief Executive Officer (CEO)

US$1.5m

Compensación total

Porcentaje del salario del CEO	37.4%
Permanencia del CEO	20.8yrs
Participación del CEO	n/a
Permanencia media de la dirección	1.5yrs
Promedio de permanencia en la Junta Directiva	11.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Sue Washer en comparación con los beneficios de Applied Genetic Technologies?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2022	n/a	n/a	-US$70m
Jun 30 2022	US$1m	US$551k	-US$69m
Mar 31 2022	n/a	n/a	-US$63m
Dec 31 2021	n/a	n/a	-US$63m
Sep 30 2021	n/a	n/a	-US$60m
Jun 30 2021	US$1m	US$530k	-US$58m
Mar 31 2021	n/a	n/a	-US$60m
Dec 31 2020	n/a	n/a	-US$57m
Sep 30 2020	n/a	n/a	-US$50m
Jun 30 2020	US$988k	US$530k	-US$46m
Mar 31 2020	n/a	n/a	-US$42m
Dec 31 2019	n/a	n/a	-US$19m
Sep 30 2019	n/a	n/a	-US$15m
Jun 30 2019	US$1m	US$514k	-US$2m
Mar 31 2019	n/a	n/a	US$2m
Dec 31 2018	n/a	n/a	-US$18m
Sep 30 2018	n/a	n/a	-US$19m
Jun 30 2018	US$1m	US$502k	-US$21m
Mar 31 2018	n/a	n/a	-US$18m
Dec 31 2017	n/a	n/a	-US$11m
Sep 30 2017	n/a	n/a	-US$4m
Jun 30 2017	US$1m	US$487k	US$407k
Mar 31 2017	n/a	n/a	US$6m
Dec 31 2016	n/a	n/a	US$10m
Sep 30 2016	n/a	n/a	US$11m
Jun 30 2016	US$2m	US$464k	-US$1m

Compensación vs. Mercado: Sue's total compensation ($USD1.47M) is above average for companies of similar size in the German market ($USD429.60K).

Compensación vs. Ingresos: Sue's compensation has increased whilst the company is unprofitable.

CEO

Sue Washer (61 yo)

20.8yrs

Permanencia

US$1,473,567

Compensación

Ms. Susan B. Washer, also known as Sue, has been the President and Chief Executive Officer of Applied Genetic Technologies Corporation since March 2002. Ms. Washer is an experienced entrepreneur with a str...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Susan Washer	President	20.8yrs	US$1.47m	sin datos
Jonathan Lieber	Chief Financial Officer	1.3yrs	US$1.00m	sin datos
Susan Schneider	Chief Medical Officer	1.1yrs	US$832.63k	sin datos
Nicholas Muzyczka	Co-Founder	23.9yrs	sin datos	sin datos
Barry Byrne	Co-Founder	23.9yrs	sin datos	sin datos
William Hauswirth	Co-Founder & Member of Ophthalmology Scientific Advisory Board	no data	sin datos	sin datos
Richard Samulski	Co-Founder	23.9yrs	sin datos	sin datos
Terence Flotte	Co-Founder	23.9yrs	sin datos	sin datos
Gerald Reynolds	Chief Accounting Officer	1.5yrs	sin datos	0% $ 0
Abraham Scaria	Chief Scientific Officer	less than a year	sin datos	sin datos
Hope D'Oyley-Gay	General Counsel	less than a year	sin datos	sin datos
David Knop	Senior Vice President of Process & Assay Development	less than a year	US$141.25k	sin datos

1.5yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: 2GT's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Susan Washer	President	19.1yrs	US$1.47m	sin datos
William Hauswirth	Co-Founder & Member of Ophthalmology Scientific Advisory Board	no data	sin datos	sin datos
Edward Hurwitz	Independent Director	10.1yrs	US$65.23k	0% $ 0
Anne VanLent	Independent Director	6.3yrs	US$79.23k	sin datos
Scott Koenig	Independent Chairman of the Board	20.7yrs	US$101.50k	0% $ 0
David Birch	Member of Ophthalmology Scientific Advisory Board	no data	sin datos	sin datos
William Aliski	Independent Director	4.3yrs	US$78.23k	0% $ 0
Peter Campochiaro	Member of Ophthalmology Scientific Advisory Board	no data	sin datos	sin datos
James Rosen	Independent Director	12.8yrs	US$72.34k	0% $ 0
Paul Kaufman	Member of Ophthalmology Scientific Advisory Board	no data	sin datos	sin datos
Stephen Daiger	Member of Ophthalmology Scientific Advisory Board	no data	sin datos	sin datos
Robert Molday	Member of Ophthalmology Scientific Advisory Board	no data	sin datos	sin datos

11.4yrs

Permanencia media

65.5yo

Promedio de edad

Junta con experiencia: 2GT's board of directors are seasoned and experienced ( 11.4 years average tenure).

This company listing is no longer active

Applied Genetic Technologies Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

Applied Genetic Technologies Corporation Announces Executive Appointments

Insufficient new directors

Insufficient new directors

Ivana Magovcevic-Liebisch Resigns from Board of Directors and Each Committee of Which She Was A Member of Applied Genetic Technologies Corporation, Effective March 9, 2022

Insufficient new directors

Recent updates

Applied Genetic Technologies Corporation(NasdaqGM:AGTC) dropped from NASDAQ Composite Index

Syncona Limited (LSE:SYNC), a fund managed by Syncona Investment Management Limited completed the acquisition of Applied Genetic Technologies Corporation (NasdaqGM:AGTC).

Applied Genetic Technologies Corporation announced delayed 10-Q filing

Insufficient new directors

Syncona Limited (LSE:SYNC), a fund managed by Syncona Investment Management Limited, entered into a definitive agreement to acquire Applied Genetic Technologies Corporation (NasdaqGM:AGTC) for $23.3 million.

Applied Genetic Technologies Corporation has completed a Follow-on Equity Offering.

Applied Genetic Technologies Corporation has completed a Follow-on Equity Offering.

Applied Genetic Technologies Receives Non-Compliance Notice from Nasdaq

Applied Genetic Technologies Corporation Announces Executive Appointments

AGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa

Applied Genetic Technologies Corporation Presents Positive 18-Month Data from Ongoing Phase 1/2 Clinical Study of AGTC-501 At the Association for Research in Vision and Ophthalmology 2022 Annual Meeting

Insufficient new directors

Insufficient new directors

Ivana Magovcevic-Liebisch Resigns from Board of Directors and Each Committee of Which She Was A Member of Applied Genetic Technologies Corporation, Effective March 9, 2022

Insufficient new directors

Applied Genetic Technologies Reports Updated Interim Three-Month Pediatric Results and Additional Adult Safety Results Out to as Long as 24 Months from Its Ongoing Phase 1/2 Dose Escalation Study of AGTC-401

Applied Genetic Technologies Corporation to Report Q2, 2022 Results on Feb 14, 2022

AGTC Exceeds Enrollment Target in SKYLINE Trial of AGTC-501 for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

Insufficient new directors

Insufficient new directors

Applied Genetic Technologies Corporation Announces Ongoing Clinical Trials in achromatopsia and X-Linked Retinitis Pigmentosa at the Fourteenth International Symposium on Retinal Degeneration

Applied Genetic Technologies Corporation(NasdaqGM:AGTC) dropped from Russell 3000E Index

Applied Genetic Technologies Corporation Reports 12-Month Data from Its Ongoing Phase 1/2 Achromatopsia Clinical Trials Showing Biologic Activity in Patients with Mutations in the ACHM B3 Gene

Otonomy, Inc. and Applied Genetic Technologies Corporation Present Preclinical Proof-Of-Concept Results for Oto-825 Gene Therapy At ASGCT Annual Meeting

Applied Genetic Technologies Corporation Advances for Manufacturing its XLRP Gene Therapy Candidate in Two Abstracts at ASGCT

Applied Genetic Technologies Corporation Reports Additional Positive Data from the Ongoing X-Linked Retinitis Pigmentosa Phase 1/2 Clinical Trial

Agtc Clinical Investigators Provide Encore Presentation of Data from the Company’s Ongoing XLRP and Achromatopsia Phase 1/2 Trials

Revenue in line with expectations

Applied Genetic Technologies Corporation to Report Q2, 2021 Results on Feb 11, 2021

New 90-day low: €3.20

Applied Genetic Technologies Corporation has completed a Follow-on Equity Offering in the amount of $74.5 million.

New 90-day low: €3.30

New 90-day low: €3.94

Revenue in line with expectations

Applied Genetic Technologies Corporation Reports Additional Positive Data from its Phase 1/2 Clinical Trial in Patients with X-Linked Retinitis Pigmentosa

Applied Genetic Technologies Corporation Plans to Release 12-Month Data for Groups 1 Through 4 Evaluating Durability of Effect and Continued Safety and Interim Data of Groups 5 and 6 Evaluating Safety and Efficacy at Higher Doses for its Phase 1/2 Clinical Trial

Applied Genetic Technologies Corporation, Annual General Meeting, Dec 16, 2020

Applied Genetic Technologies Corporation Joins the My Retina Tracker® Program as A New Scientific Collaborator

New 90-day low: €4.14

Full year earnings released - €2.17 loss per share

Applied Genetic Technologies Corporation to Report Q4, 2020 Results on Sep 09, 2020

New 90-day low - €4.16

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad